Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06035744 · ClinicalTrials.gov registry record · Phase 1

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Cullinan Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
86
Enrollment target
5
Study locations

NCT06035744 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 86 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06035744, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Cullinan Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
86 participants
Enrollment target
5
Study locations

Study Summary

CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG CLN-617

Study Locations (5)

California

  • USC Norris Comprehensive Cancer Center - Los Angeles

Florida

  • Orlando Health - Orlando

Illinois

  • University of Chicago - Chicago

Texas

  • MD Anderson - Houston

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2023-12-12
Est. Completion 2028-06
Phase Phase 1

Sponsor

Cullinan Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06035744

The ClinicalTrials.gov registry entry for NCT06035744 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06035744 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06035744 about?

NCT06035744 is a clinical study titled "CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

What is the current status of trial NCT06035744?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-12-12. Estimated completion is 2028-06.

What conditions does trial NCT06035744 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06035744?

The interventions under investigation include: Pembrolizumab (DRUG), CLN-617 (DRUG).

Who is sponsoring clinical trial NCT06035744?

This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06035744 being conducted?

This trial has 5 study locations across California, Florida, Illinois, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.